Schønnemann, K. R., Jensen, H. A., Yilmaz, M., Jensen, B. V., Larsen, O., & Pfeiffer, P. (2008). Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer. Nature Publishing Group.

Schønnemann, K R., H A. Jensen, M. Yilmaz, B V. Jensen, O. Larsen, and P. Pfeiffer. Phase II Study of Short-time Oxaliplatin, Capecitabine and Epirubicin (EXE) As First-line Therapy in Patients With Non-resectable Gastric Cancer. Nature Publishing Group, 2008.

Schønnemann, K R., et al. Phase II Study of Short-time Oxaliplatin, Capecitabine and Epirubicin (EXE) As First-line Therapy in Patients With Non-resectable Gastric Cancer. Nature Publishing Group, 2008.